Physician profile
Ramona Scott
NPI 1881859007
$24,832.98
in general payments reported to CMS, 2019-2025
11 companies · $3,080 in 2025
The $3,080 reported for 2025 was more than what 98% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,657 · 2022: $1,451 · 2023: $12K · 2024: $4,032 · 2025: $3,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,090 · Food and Beverage: $1,434 · Travel and Lodging: $624 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,477.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,090.00 |
| Food and Beverage | $1,434.07 |
| Travel and Lodging | $624.10 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $16,064.43 | 2022-2025 | Veozah |
| Organon LLC | $6,796.56 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $1,386.23 | 2021 | |
| Mayne Pharma Commercial LLC | $212.25 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $160.87 | 2023 | Myfembree |
| Exeltis, USA INC. | $81.90 | 2022-2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $42.59 | 2025 | |
| Sage Therapeutics, LLC | $35.30 | 2025 | Zurzuvae |
| Pfizer INC. | $21.76 | 2025 | |
| Daiichi Sankyo INC. | $16.93 | 2023 | Injectafer |
| Avion Pharmaceuticals | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramona Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.